Background: Neoadjuvant chemotherapy has shown a modest benefit in muscle-invasive bladder cancer patients; however, the subset of patients most likely to benefit has not been identified. BRCA1 plays a central role in DNA repair pathways and low BRCA1 expression has been associated with sensitivity to cisplatin and longer survival in lung and ovarian cancer patients.
introduction
Cystectomy with pelvic lymph node dissection remains the mainstay of treatment of muscle-invasive bladder cancer. However, 50% of patients will develop distant metastases after surgical treatment and die of the disease [1] . This prognosis worsens in tumors involving perivesical fat or adjacent organs (cT3b-4) and those with lymph node involvement. In these patients, cystectomy alone offers a cure rate of only 20%-30% [2] [3] [4] .
Based on the proven efficacy of cisplatin-based chemotherapy in advanced bladder cancer [5] , neoadjuvant chemotherapy has been explored in invasive bladder cancer [6] . In the largest neoadjuvant trial, carried out by European Organization for Research and Treatment of Cancer/Medical Research Council (UK), 976 patients with muscle-invasive bladder cancer were randomly assigned to receive either neoadjuvant chemotherapy with cisplatin, methotrexate, and vinblastine (CMV) or no chemotherapy, followed by local therapy (cystectomy or radiotherapy). An improvement of 6% (50% versus 44%) was observed in 5-year survival in patients treated with neoadjuvant chemotherapy [7, 8] . In a more recent Southwest Oncology Group randomized trial (SWOG 8710) in patients with muscle-invasive bladder cancer stage cT2-4N0M0, neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) led to a significant improvement in median survival (77 versus 46 months), with a reduction in estimated risk of death of 25% compared with cystectomy alone [9] . Moreover, in two metaanalyses, each including >2600 patients from randomized trials, a positive but modest benefit for neoadjuvant chemotherapy was observed, with an absolute improvement in survival of 5%-6.5% with cisplatin-based chemotherapy [10, 11] . In spite of these results, neoadjuvant chemotherapy is not a standard approach in many institutions [12, 13] including treatment-related toxicity, the potential negative impact of delaying cystectomy in chemorefractory patients [14, 15] , and the absence of predictive markers to identify patients who will respond to neoadjuvant chemotherapy. There are no baseline clinical characteristics that help us to predict response to neoadjuvant treatment, but it is well established that patients who obtain a pathological complete response (pCR) after chemotherapy have a higher probability of longterm survival than those with residual tumors in the cystectomy tissue [9] . Unfortunately, we are still not able to predict which patients will fall into each prognostic group. The breast cancer susceptibility gene 1 (BRCA1) encodes a 220-kDa nuclear protein that responds to DNA damage by participating in multiple biological processes, including gene transcription, DNA damage repair, cell growth, and apoptosis [16] . In response to DNA damage, BRCA1 is recruited to the sites of DNA breaks, modulating radioresistance and chemoresistance through its important role in transcriptioncoupled nucleotide excision repair, homologous recombination repair, and nonhomologous end joining [17] . Decreased BRCA1 messenger RNA (mRNA) expression in breast cancer cell lines increases sensitivity to cisplatin and resistance to antimicrotubule agents, like paclitaxel, vinorelbine, and vincristine [18, 19] . Moreover, low BRCA1 levels were associated with a better prognosis to cisplatin-based chemotherapy in ovarian [20] and non-small-cell lung cancer (NSCLC) [21] .
In order to investigate the predictive role of BRCA1 mRNA expression in invasive bladder cancer, we retrospectively analyzed tumor samples from bladder cancer patients treated with neoadjuvant cisplatin-based chemotherapy and correlated BRCA1 levels with pathological response to chemotherapy and overall survival.
patients and methods patients
Between 1991 and 2007, 98 patients with muscle-invasive locally advanced bladder cancer were treated with neoadjuvant chemotherapy in our institution. After transurethral resection (TUR), all patients were clinically staged by chest X-ray and computerized tomography (CT) of the abdomen and pelvis. Only patients with locally advanced tumors with extravesical disease (T3-4 and/or regional lymph nodes) were candidates for neoadjuvant chemotherapy, and the final decision was based on the consensus of the attending urologist and medical oncologist. Patients were required to have no serious alteration in hematologic, renal, and hepatic functions and a performance status (PS) of zero to two. Patients received a median of three cycles of cisplatin-based chemotherapy. Patients were treated with CMV from 1991 to 2000 and with cisplatin plus gemcitabine from 2001 to 2007. After chemotherapy, patients were restaged with a CT scan of the abdomen and pelvis and a cystectomy was carried out if feasible. The study was approved by the institutional ethics review board for gathering all materials and patient data.
BRCA1 mRNA expression
Tumor tissue was obtained from TUR before the administration of neoadjuvant chemotherapy. BRCA1 mRNA expression was assessed in formalin-fixed paraffin-embedded tumor tissue from 57 patients; in the remaining 41 patients, tumor tissue was unavailable or insufficient for BRCA1 assessment. Intratumoral BRCA1 mRNA expression levels were assessed by real-time quantitative polymerase chain reaction (RT-PCR). Total RNA was isolated after laser-capture microdissection that ensured a minimum of 90% of tumor cells. In previous validation experiments (M. Taron, unpublished data), we had found that the minimum number of tumor cells required for BRCA1 expression analysis was 4400 cells, which corresponds to an average of 2.2 mm 2 of tumor tissue from a section of 4 l.
This was the median number of microdissected cells in the paraffinembedded tumor tissues used in this study. After deparaffination with standard xylene and alcohol process, samples were subjected to lysis in a buffer containing Tris-chloride, EDTA, sodium dodecyl sulfate, and proteinase K. RNA was then extracted with phenol-chlorofrom-isoamyl alcohol followed by precipitation with isopropanolol in the presence of glycogen and sodium acetate. RNA was resuspended in diethyl pyrocarbonate water (Ambion Inc., Austin, TX) and treated with DNAse I to avoid DNA contamination. Complementary DNA (cDNA) was synthesized using M-MLV retrotranscriptase enzyme. Template cDNA was added to TaqMan Universal Master Mix in a 12.5-ml reaction with specific primers and probe for each gene. The endogenous reference gene was b-actin. Gene expression was quantified using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) [22] .
statistical analyses
Median values and ranges were calculated for quantitative variables and gene mRNA expression. Qualitative variables were summarized by absolute frequencies and percentages. In order to provide an easily interpretable evaluation of the effect of BRCA1 mRNA expression, gene expression values were divided into terciles. Hazard ratios were calculated with the univariate Cox model, and Kaplan-Meier survival curves were compared with the log-rank test. All tests of statistical significance were two sided, with a statistical power of 80%, and significance was set at 0.05. For potential multiple comparisons, the P values were corrected with the Bonferroni correction. Analyses were carried out using Statistical Package for the Social Sciences (SPSS) for Windows version 17 (SPSS Inc., Chicago, IL) and S-Plus 6.1 for Windows.
results patient characteristics Table 1 shows the clinicopathologic characteristics for all patients (98), for the 57 patients in whom BRCA1 mRNA expression was analyzed, and for the 41 patients with insufficient tumor tissue for BRCA1 assessment. No differences were observed between patients in whom BRCA1 was assessed and those in whom it was not assessed. Thirty-six patients (63%) received CMV and the remaining 21 (37%) received cisplatin plus gemcitabine. The median number of cycles of chemotherapy given was 3 (range, 2-6). Cystectomy was carried out in 53 patients (93%), 5 of whom had positive surgical margins; these 5 patients received postoperative radiotherapy. Four patients were considered ineligible for surgery due to early death related to chemotherapy toxicity, poor PS, tumor progression, or patient refusal. A significant pathological response-defined either as no tumor found in the pathological analysis of the cystectomy (pCR) or only superficial residual tumor (pTis/pT1)-was observed in 28 patients (49%), including 15 patients (26%) with a pCR. Eleven patients (19%) were classified as pT2 and 5 (9%) as pT3-4N0. In the remaining nbine patients, regional lymph node involvement was observed in the pathological analysis of lymphadenectomy samples. (Table 2 ). Median overall survival in patients with low levels was 124 months (95% CI 57.7-190.3 months), while it was not reached in patients with intermediate levels, and it was 34 months (95% CI 14.5-53.5 months) in those with high levels (P = 0.008). Because survival times were similar in patients with low and intermediate levels, these two groups of patients were combined for further statistical analyses. In patients with low/ intermediate BRCA1 levels, median survival was 168 months (95% CI 54.9-281.1 months) and 5-year survival was 64%, whereas in patients with high levels, median survival was 34 months (95% CI 14.5-53.5 months) and 5-year survival was 12% (P = 0.002) (Figure 1 ). Patients with low/intermediate BRCA1 levels had a higher pathological response rate than those with high levels. Sixty-six percent (24 of 39) of patients with low/intermediate levels, compared with 22% (4 of 18) of those with high levels, attained a pathological response (pT0-1) (P = 0.01).
Among 36 patients treated with CMV, median survival was 168 months in those with low/intermediate BRCA1 levels and 41 months in those with high levels (P = 0.03). Among 21 patients treated with cisplatin plus gemcitabine, median survival in patients with low/intermediate BRCA1 levels was not reached, whereas in patients with high levels, it was 34 months (P = 0.09).
A univariate analysis of overall survival was carried out including the following variables: age, histology, lymphovascular invasion, hydronephrosis, clinical stage, chemotherapy regimen, resection, pathological stage, and BRCA1 expression. Low/intermediate BRCA1 levels, absence of lymphovascular invasion, absence of lymph nodes at baseline clinical staging, radical cystectomy, and pathological response (pT0-1) were associated with longer survival (Table 3 ). In the multivariate analysis, only lymphovascular invasion and BRCA1 mRNA expression levels emerged as independent prognostic factors for overall survival (hazard ratios: lymphovascular invasion, 6.1, P < 0.0001; high BRCA1 expression, 2.7, P = 0.02) ( Table 4) .
discussion
In the present study, we have observed a significant correlation between BRCA1 mRNA levels and response and survival in locally advanced bladder cancer patients treated with neoadjuvant cisplatin-based chemotherapy. The subgroup of patients with low and intermediate BRCA1 levels obtained a significant benefit from preoperative chemotherapy, with a 5-year survival rate of 64%, in spite of the fact that the majority of patients had locally advanced disease and/or lymph node involvement. In contrast, the subgroup of patients with the highest levels of BRCA1 expression had a poor prognosis, with a 5-year survival rate of only 12%. In the multivariate (20) 7 (35) TCC, transitional cell carcinoma; CMV, cisplatin, methotrexate, and vinblastine; mRNA, messenger RNA. analysis, BRCA1 expression levels emerged as an independent prognostic marker of survival, while no baseline clinicopathologic characteristic except lymphovascular invasion had a prognostic impact on survival. Few genetic markers have been proven to predict chemotherapy efficacy in bladder cancer. Expression of emmprin, a modulator of matrix metalloproteinases, and survivin have been identified as prognostic factors for response and survival in advanced bladder cancer patients treated with cisplatin-based chemotherapy [23] . In contrast, findings regarding alterations in p53 expression [22, [24] [25] [26] and other markers involved in cell cycle regulation and apoptosis [27, 28] have been contradictory. Although for practical reasons, studies have often concentrated on the assessment of one genetic marker, it seems likely that multiple markers can influence chemotherapy efficacy. While high MDR1 expression determined by RT-PCR was associated with a shorter survival in patients with locally advanced bladder cancer treated with adjuvant cisplatin/methotrexate [29] , Takata et al. [30] used microarray analysis to identify a set of genes related to response to neoadjuvant chemotherapy. In another study of bladder cancer patients treated with neoadjuvant M-VAC, using multivariate gene expression models based on biomarkers of in vitro drug sensitivity, the 3-year overall survival for patients with favorable gene expression scores was 81% versus 33% for those with less favorable scores [31] .
Several studies have shown that the analysis of DNA damage repair pathways can provide useful information for customizing therapy. For example, in a study of metastatic bladder cancer patients treated with a cisplatin-based regimen, ERCC1 expression was associated with improved outcome, although no differences in survival were observed according to BRCA1 expression [32] . However, in 75% of the patients, paclitaxel was administered in combination with cisplatin plus gemcitabine and the addition of taxanes may have counteracted the positive impact of low BRCA1 expression. More recently, these authors have shown that ERCC1 expression detected by immunohistochemistry can predict disease-specific survival in advanced bladder cancer patients treated with cisplatin-based chemotherapy [33] . In contrast, in a study of resected NSCLC patients, although a significant relationship between BRCA1 and ERCC1 expression was observed, only BRCA1 expression emerged as an independent prognostic factor [34] .
The results of the present study are consistent with findings in preclinical studies in breast and ovarian cancer cells [18, 19] and in clinical studies [20, 21] . In patients with locally advanced NSCLC treated with cisplatin plus gemcitabine, low BRCA1 levels correlated with a longer survival in comparison with high BRCA1 levels [21] . In a retrospective study in ovarian cancer, among patients treated with platinum-based chemotherapy, those with low and intermediate BRCA1 levels had longer survival than those with high levels, whereas among patients treated with taxanes, a better outcome was attained by those with high BRCA1 levels [20] . In a study of 102 NSCLC patients, high BRCA1 mRNA levels were associated with better response and decreased risk of progression to docetaxel plus gemcitabine [35] . This differential modulating effect of BRCA1 mRNA expression was also observed in tumor cells isolated from malignant effusions of NSCLC and gastric cancer patients, where BRCA1 mRNA levels correlated negatively with cisplatin sensitivity and positively with docetaxel sensitivity [36] .
Taken together, these studies suggest that BRCA1 may have a dual role as both a prognostic marker and a predictor of sensitivity to cisplatin and taxanes. The impact of BRCA1 expression on pathological response observed in the present study reinforces this predictive role as a marker of sensitivity to cisplatin-based chemotherapy, making it a useful tool for selecting bladder cancer patients who will benefit from neoadjuvant cisplatin-based chemotherapy. At the same time, early identification of potential nonresponders would allow us to consider alternative treatments and avoid ineffective therapies. Thus, the option of taxane-based therapy for patients with high BRCA1 expression could be explored, as has been suggested in studies of ovarian and lung cancer patients [20, 35] .
In conclusion, although our findings should be interpreted cautiously due to the limited number of patients included, our data lead us to speculate that the assessment of BRCA1 mRNA expression can be used to customize therapy and improve outcome in bladder cancer patients. Further studies with a larger number of patients and other molecular markers are warranted to confirm these results. 
